Roche's Cobas COVID Test Scores EUA For Asymptomatic People

by Vandana Singh, Benzinga Editor

May 18, 2021 6:37 AM | 28 seconds read |

Roche Holdings AG’s RHHBY Cobas SARS-CoV-2 Test has received U.S. authorization for testing individuals without symptoms or reasons to suspect a COVID-19 infection.
“The high-throughput, highly sensitive Cobas SARS-CoV-2 Test under FDA Emergency Use Authorization can now be used to test individual or pooled samples from people without symptoms or other reasons to suspect COVID-19,” Roche said in a statement.
The test applies to pooled samples containing up to and including six individual samples.
Price Action: RHHBY shares closed at $42.2 on Monday.

Posted In: Biotech News Health Care FDA General Briefs Covid-19 Emergency Use Authorization

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.